BRIEF—Daiichi Sankyo makes senior executive changes

Japan’s Daiichi Sankyo has announced senior-level organizational changes, appointing Junichi Koga as global head of R&D and Ken Keller as president and CEO of the group’s US subsidiary.

The changes are aimed at helping realize the company's long-term strategy, which includes delivering seven distinct new molecular entities in oncology by 2025, as well as specialty medicines.

Mr Keller said: "Close connection between our commercial and R&D organizations in the USA and globally will support the next phase of our transformation and growth as a science-based, patient-centered company with a primary focus on oncology."